BioCentury
ARTICLE | Clinical News

RT002: Ph II started

November 4, 2016 7:58 PM UTC

Revance began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate a single injection of RT002 in 60 patients....

BCIQ Company Profiles

Revance Therapeutics Inc.